PGEN
PrecigenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source evidence improved versus the prior baseline: PAPZIMEOS is approved, Q4 2025 included the first partial quarter of US sales, management described stronger Q1 2026 demand, broad payer access, and a permanent J-code effective April 1, 2026, which together support a real commercialization path [#PR-2026-03-25].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.4.
What can break
Balance-sheet risk remains material for a small biopharma: the 10-K shows $100.0 million of long-term debt and an operating loss in 2025, so weaker uptake could reopen financing concerns [#10-K-2026-03-25].
Momentum
70
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $7.50 · Bear $2.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $8.50
Why
Momentum70 · Δ7d -3.4
Value41 · Δ7d +0.1
Sentiment69 · Δ7d +6.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
70
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
+12.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
69
33% active weight
Current posture
7d trendImproving
Δ7d
+6.5
Δ21d
+10.6
Why this grade
Composite grade B. Momentum 70.4 / Value 41.1 / Sentiment 69.3
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.38B
Beta
1.07
Shares Out
353.82M
P/E (TTM) · Derived
-8.3
P/S (TTM)
234.42
P/FCF (TTM) · Derived
-15.31
Rev YoY
+206.6%
EPS YoY
-1118.7%
Gross Margin
+30.3%
Op Margin
-1860.2%
Net Debt
-$97.91M
Current Ratio
4.04
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology